ArticleTransplantation and cellular therapy2026

Venetoclax-Augmented RIC Allogeneic HCT With PTCy-Based GVHD Prophylaxis and Venetoclax/Azacitidine Maintenance for Poor Risk MDS and AML.

H Moses Murdock et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.